Home > Qtrly Results > GLENMARK PHARMACEUTICALS

GLENMARK PHARMACEUTICALS
Quarterly Results Analysis [Jun2026]

GLENMARK PHARMACEUTICALS is part of below Screeners ↓
Best Quarterly Growth Mid Cap Stocks
COMMUNITY POLL
for GLENMARK PHARMACEUTICALS
Please provide your vote to see the results

GLENMARK PHARMACEUTICALS Quarterly Results

Consolidated Jun2026
UnAudited
Mar2026
UnAudited
Dec2025
UnAudited
Sep2025
UnAudited
Jun2025
UnAudited
Mar2025
UnAudited
Dec2024
UnAudited
Sep2024
UnAudited
Revenues ₹4,018 Cr ₹3,771 Cr ₹3,901 Cr ₹6,047 Cr ₹3,264 Cr ₹3,256 Cr ₹3,388 Cr ₹3,434 Cr
Expenses ₹3,214 Cr ₹3,008 Cr ₹3,031 Cr ₹3,687 Cr ₹2,684 Cr ₹2,695 Cr ₹2,787 Cr ₹2,832 Cr
Operating Income ₹805 Cr ₹763 Cr ₹870 Cr ₹2,360 Cr ₹581 Cr ₹561 Cr ₹600 Cr ₹602 Cr
Other Income ₹66 Cr ₹189 Cr ₹44 Cr ₹201 Cr ₹26 Cr ₹12 Cr ₹31 Cr ₹39 Cr
Interest ₹54 Cr ₹43 Cr ₹41 Cr ₹66 Cr ₹58 Cr ₹67 Cr ₹52 Cr ₹48 Cr
Depreciation ₹173 Cr ₹148 Cr ₹154 Cr ₹141 Cr ₹130 Cr ₹125 Cr ₹123 Cr ₹120 Cr
Profit Before Tax ₹643 Cr ₹388 Cr ₹534 Cr ₹967 Cr ₹96 Cr ₹8 Cr ₹456 Cr ₹473 Cr
Profit After Tax ₹483 Cr ₹301 Cr ₹403 Cr ₹610 Cr ₹47 Cr ₹4 Cr ₹348 Cr ₹354 Cr
EPS ₹17.11 ₹10.68 ₹14.29 ₹21.63 ₹1.66 ₹0.16 ₹12.33 ₹12.55
Industry Peers & Returns1W1M1Y
GLENMARK PHARMACEUTICALS 5% 1% 7.8%
SUN PHARMACEUTICAL INDUSTRIES -0.1% 0.5% 14%
DIVIS LABORATORIES -0.9% 21.1% 25.6%
TORRENT PHARMACEUTICALS -1.3% 1.1% 32.7%
CIPLA 0.2% 2.1% -5.1%
DR REDDYS LABORATORIES 0.2% -7.7% -7.5%
MANKIND PHARMA -1.4% -3.7% -5.3%
LUPIN -0.7% -5.7% 24%
ZYDUS LIFESCIENCES -0.1% -3.9% 14.1%

GLENMARK PHARMACEUTICALS Quarterly Revenues

Revenues
Q-o-Q

6.57 %

Y-o-Y

23.10 %

Quarters Revenues % Change
Jun2026 ₹4,018 Cr
6.57
Mar2026 ₹3,771 Cr
-3.33
Dec2025 ₹3,901 Cr
-35.49
Sep2025 ₹6,047 Cr
85.23
Jun2025 ₹3,264 Cr
0.25
Mar2025 ₹3,256 Cr
-3.88
Dec2024 ₹3,388 Cr
-1.35
Sep2024 ₹3,434 Cr -

GLENMARK PHARMACEUTICALS Quarterly Operating Profit

Operating Profit
Q-o-Q

5.53 %

Y-o-Y

38.63 %

Quarters Operating Profit % Change
Jun2026 ₹805 Cr
5.53
Mar2026 ₹763 Cr
-12.32
Dec2025 ₹870 Cr
-63.14
Sep2025 ₹2,360 Cr
306.45
Jun2025 ₹581 Cr
3.47
Mar2025 ₹561 Cr
-6.53
Dec2024 ₹600 Cr
-0.28
Sep2024 ₹602 Cr -
Operating Margins
Q-o-Q

-0.94 %

Y-o-Y

12.65 %

Quarters Operating Margin% % Change
Jun2026 20.03%
-0.94
Mar2026 20.22%
-9.33
Dec2025 22.3%
-42.85
Sep2025 39.02%
119.46
Jun2025 17.78%
3.19
Mar2025 17.23%
-2.77
Dec2024 17.72%
1.08
Sep2024 17.53% -

GLENMARK PHARMACEUTICALS Quarterly Profit After Tax

Profit After Tax(PAT)
Q-o-Q

60.24 %

Y-o-Y

927.88 %

Quarters Profit After Tax % Change
Jun2026 ₹483 Cr
60.24
Mar2026 ₹301 Cr
-25.27
Dec2025 ₹403 Cr
-33.94
Sep2025 ₹610 Cr
1,199.54
Jun2025 ₹47 Cr
971.46
Mar2025 ₹4 Cr
-98.74
Dec2024 ₹348 Cr
-1.82
Sep2024 ₹354 Cr -
PAT Margins
Q-o-Q

50.44 %

Y-o-Y

734.72 %

Quarters PAT Margin(%) % Change
Jun2026 12.02 %
50.44
Mar2026 7.99 %
-22.73
Dec2025 10.34 %
2.38
Sep2025 10.1 %
601.39
Jun2025 1.44 %
1,007.69
Mar2025 0.13 %
-98.73
Dec2024 10.27 %
-0.48
Sep2024 10.32 % -

GLENMARK PHARMACEUTICALS Quarterly Earnings Per Share (EPS)

EPS
Q-o-Q

60.21 %

Y-o-Y

930.72 %

Quarters EPS % Change
Jun2026 ₹17.11
60.21
Mar2026 ₹10.68
-25.26
Dec2025 ₹14.29
-33.93
Sep2025 ₹21.63
1,203.01
Jun2025 ₹1.66
937.50
Mar2025 ₹0.16
-98.70
Dec2024 ₹12.33
-1.75
Sep2024 ₹12.55 -

You may also like the below Video Courses